Fenoterol
GENITO URINARY SYSTEM AND SEX HORMONES
Also known as: fenoterol HCl, fenoterol hydrobromide, fenoterol hydrochloride, phenoterol
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Fenoterol is a drug catalogued in DrugCentral. It was first approved by the YEAR INTRODUCED in 1965. DrugCentral lists 4 molecular targets, including ADRB3, ADRB1 and Adrb2.
- Molecular targets: ADRB3, ADRB1, Adrb2 and ADRB2 (4 listed in DrugCentral).
- ATC code: G02CA03 (Sympathomimetics, labour repressants).
- Molecular formula: C17H21NO4; molecular weight 303.36 g/mol.
Mechanism & targets
Molecular targets (4)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Beta-3 adrenergic receptor | ADRB3 | agonist | EC50 7.60 |
| Beta-1 adrenergic receptor | ADRB1 | agonist | EC50 7.50 |
| Beta-2 adrenergic receptor | Adrb2 | unknown | IC50 7.22 |
| Beta-2 adrenergic receptor | ADRB2 | agonist | EC50 6.90 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 1965-01-01 | YEAR INTRODUCED | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
G02CA03 | GENITO URINARY SYSTEM AND SEX HORMONES › OTHER GYNECOLOGICALS › OTHER GYNECOLOGICALS › Sympathomimetics, labour repressants |
R03AC04 | RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Selective beta-2-adrenoreceptor agonists |
R03AL01 | RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS, INHALANTS › Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids |
R03CC04 | RESPIRATORY SYSTEM › DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES › ADRENERGICS FOR SYSTEMIC USE › Selective beta-2-adrenoreceptor agonists |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Appendicolith | 238.2 |
| Myasthenia gravis | 215.0 |
| Blood phosphorus increased | 213.6 |
| Hyperphosphataemia | 201.6 |
| Appendicitis | 187.6 |
| Blood uric acid increased | 168.8 |
| Chronic obstructive pulmonary disease | 168.4 |
| Ventricular fibrillation | 164.1 |
| Hypophosphataemia | 146.4 |
| Bacterial infection | 144.5 |
| Cardiogenic shock | 140.1 |
| Iron deficiency | 137.7 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Fenoterol is on its molecule page.
| Molecular formula | C17H21NO4 |
|---|---|
| Molecular weight | 303.36 g/mol |
| CAS number | 13392-18-2 |
| InChIKey | LSLYOANBFKQKPT-UHFFFAOYSA-N |
| PubChem CID | 3343 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
How does Fenoterol work?
Its molecular targets in DrugCentral include ADRB3 (agonist), ADRB1 (agonist), Adrb2 and ADRB2 (agonist).
When was Fenoterol first approved?
Fenoterol was first approved by the YEAR INTRODUCED in 1965.
What is the chemical formula of Fenoterol?
Fenoterol has the molecular formula C17H21NO4 and a molecular weight of 303.36 g/mol.
Browse: all drugs starting with F · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 1155 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL32800 — compound record and bioactivity
- PubChem CID 3343 — chemical identifiers
- DrugBank DB01288 — drug record
- FDA UNII 22M9P70OQ9 — substance identity
- UniProt P13945 (ADRB3) — target protein
- UniProt P08588 (ADRB1) — target protein
- UniProt P07550 (ADRB2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.